Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

about

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Diabetes consequences in the fetus liver of the non-obese diabetic mice

P2860

Q26772800-ED1D2618-6C62-4A07-B4BB-637971C2D3EE Q28068710-2830B912-22FE-48C3-8651-377E97C2E056 Q37737786-8C8BA121-AA17-4F90-9AB1-D32353FD7B1C

P2860

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

Item

http://www.wikidata.org/entity/Q41152963

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

@en

type

Item

label

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

@en

prefLabel

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

@en

P1476

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

@en

P2093

A M M Coelho

http://www.w3.org/2001/XMLSchema#string

C P Oliveira

http://www.w3.org/2001/XMLSchema#string

D F Barbeiro

http://www.w3.org/2001/XMLSchema#string

F J Carrilho

http://www.w3.org/2001/XMLSchema#string

H P Souza

http://www.w3.org/2001/XMLSchema#string

I V A Pereira

http://www.w3.org/2001/XMLSchema#string

J T Stefano

http://www.w3.org/2001/XMLSchema#string

L A C D'Albuquerque

http://www.w3.org/2001/XMLSchema#string

M M Torres

http://www.w3.org/2001/XMLSchema#string

M P Xerfan

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

A new mathematical model for relative quantification in real-time RT-PCR

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Severe liver steatosis correlates with nitrosative and oxidative stress in rats

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

Mitochondrial abnormalities in non-alcoholic steatohepatitis.

Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease.

Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches

Liver fibrogenesis: a new role for the renin-angiotensin system.

P304

408-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/1414-431X20143962

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Mazo

Bruno Cogliati

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25714891

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

4445663

http://www.w3.org/2001/XMLSchema#string

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

about

P2860

P2860

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932